已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

医学 打开标签 内科学 肿瘤科 布仑妥昔单抗维多汀 临床研究阶段 弥漫性大B细胞淋巴瘤 淋巴瘤 临床试验 霍奇金淋巴瘤
作者
Hervé Tilly,Franck Morschhauser,Nancy L. Bartlett,Amitkumar Mehta,Gilles Salles,Corinne Haïoun,Javier Muñoz,Andy I. Chen,Kathryn S. Kolibaba,Dan Lü,Mark Yan,Elicia Penuel,Jamie Hirata,Calvin Lee,Jeff P. Sharman
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (7): 998-1010 被引量:138
标识
DOI:10.1016/s1470-2045(19)30091-9
摘要

Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, we evaluated the safety and preliminary activity of polatuzumab vedotin in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated diffuse large B-cell lymphoma.This was an open-label, non-randomised study composed of a phase 1b dose escalation and a phase 2 dose expansion at 11 hospitals and health centres in the USA and France. Patients aged 18 years or older with B-cell non-Hodgkin lymphoma were eligible. Exclusion criteria included peripheral neuropathy with grade greater than 1, major surgery within 4 weeks before enrolment, known CNS involvement of lymphoma, and uncontrolled heart disease. Phase 1b dose escalation had a three-plus-three design and established the recommended phase 2 dose. Phase 2 expansion evaluated the recommended phase 2 dose of polatuzumab vedotin in patients with newly diagnosed diffuse large B-cell lymphoma with an International Prognostic Index (IPI) of 2-5. Patients received cyclophosphamide 750 mg/m2 on day 1 intravenously, doxorubicin 50 mg/m2 on day 1 intravenously, and prednisone 100 mg once daily on days 1-5 of each 21-day cycle orally (CHP), plus either rituximab 375 mg/m2 intravenously on day 1 of each cycle (R-CHP) or obinutuzumab 1000 mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of the following cycles (G-CHP). Polatuzumab vedotin was administered on day 2 of cycles 1 and 2, and on day 1 of the following cycles at 1·0-2·4 mg/kg during the escalation phase and at the recommended phase 2 dose during the expansion phase. Treatment could last six or eight cycles, depending on investigator preference. The primary endpoints of the study were safety and tolerability, and determination of the maximum tolerated dose (or recommended phase 2 dose) of polatuzumab vedotin. All endpoints were analysed per protocol in the safety evaluable population, defined as all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01992653.Between Dec 4, 2013, and July 26, 2016, 85 patients were enrolled. 82 patients were included in the safety and activity evaluable populations, 25 in phase 1b and 57 in phase 2. In light of information from other studies using polatuzumab vedotin reported during this study, in which the safety profile associated with exposure to polatuzumab vedotin at doses higher than 1·8 mg/kg every 3 weeks was not outweighed by any clinical benefit, the recommended phase 2 dose was set to 1·8 mg/kg in the R-CHP cohort and no higher doses were explored in this study. 66 patients with newly diagnosed diffuse large B-cell lymphoma received the polatuzumab vedotin recommended phase 2 dose (45 R-CHP; 21 G-CHP). In 66 patients with diffuse large B-cell lymphoma who received the recommended phase 2 dose, the most common adverse events of grade 3 or worse were neutropenia (20 [30%]), febrile neutropenia (12 [18%]), and thrombocytopenia (six [9%]). Among the 70 patients (any histology) who received the recommended phase 2 dose, 19 (27%) had grade 1 peripheral neuropathy, eight (11%) grade 2, and two (3%) grade 3. Four deaths were reported during follow-up: two treatment-related (one complication of atrial fibrillation and one septic shock) and two due to disease progression. As of the cutoff date of Dec 29, 2017, median follow-up time was 21·5 months (IQR 16·7-24·3) for the untreated diffuse large B-cell lymphoma cohort treated at the polatuzumab vedotin recommended phase 2 dose. 59 (89%) patients achieved an overall response at end of treatment (51 [77%] patients had a complete response, and eight [12%] patients had a partial response).The safety of incorporating polatuzumab vedotin to R-CHP or G-CHP was as expected and managable. Preliminary clinical activity in newly diagnosed diffuse large B-cell lymphoma seems promising and encouraged a phase 3 trial comparing polatuzumab vedotin with R-CHP to R-CHOP.F Hoffmann-La Roche/Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
2秒前
斯文败类的应助被令狐大侠采纳,获得30
2秒前
2秒前
bkagyin的应助被令狐大侠采纳,获得10
2秒前
嘻嘻哈哈的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.4的应助被令狐大侠采纳,获得10
2秒前
2秒前
汉堡包的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.2的应助被令狐大侠采纳,获得10
2秒前
3秒前
xxzxg_nono完成签到,获得积分10
3秒前
lys完成签到 ,获得积分10
3秒前
mps完成签到 ,获得积分10
6秒前
悠悠球完成签到,获得积分10
6秒前
793967195发布了新的文献求助10
6秒前
zilicai完成签到,获得积分10
8秒前
L_Gary完成签到 ,获得积分10
8秒前
9秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
10秒前
xinyuanjia的应助被令狐大侠采纳,获得10
10秒前
xinyuanjia的应助被令狐大侠采纳,获得30
11秒前
ding的应助被令狐大侠采纳,获得10
11秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
11秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
11秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
11秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
12秒前
秋风的应助被令狐大侠采纳,获得10
12秒前
喜悦如萱完成签到,获得积分10
12秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
12秒前
13秒前
13秒前
13秒前
洁净醉波完成签到 ,获得积分10
13秒前
洋芋二号发布了新的文献求助10
15秒前
洋芋二号发布了新的文献求助10
15秒前
洋芋二号发布了新的文献求助10
15秒前
洋芋二号发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184828
求助须知:如何正确求助?哪些是违规求助? 9573791
关于积分的说明 21833034
捐赠科研通 7782127
什么是DOI,文献DOI怎么找? 3434405
关于科研通互助平台的介绍 2558545
邀请新用户注册赠送积分活动 2481067